Zydus announces settlement with Upsher-Smith Laboratories, Inc. on Qudexy XR (topiramate) extended-release capsules
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated January 13, 2017, titled "Zydus announces settlement with Upsher-Smith Laboratories, Inc. on Qudexy XR (topiramate) extended-release capsules". Shareholding for the Period Ended December 31, 2016
Cadila Healthcare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2016. For more details, kindly Click here Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended December 31, 2016
Cadila Healthcare Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Updates
Cadila Healthcare Ltd has informed BSE that the Company is going to participate in JP Morgan Investor Conference scheduled to be held on January 09, 2017 to January 12, 2017 in US. Q3 results on Jan 31, 2017
Cadila Healthcare Ltd has informed BSE that the meeting of the Board of Directors of the Company will be held on January 31, 2017 to consider inter alia, to approve the un-audited financial results for the quarter / nine months ended on December 31, 2016 (Q3).Further, as per Code of Conduct for prevention of Insider Trading adopted by the Company under SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window shall remain... Cadila Healthcare: US FDA resolution key for re-rating
Recent brand acquisition will help boost domestic sales US FDA pulls up Cadila for misbranding drug
US FDA pulls up Cadila for misbranding drugThe company has been researching on the drug to treat fatty liver disease or non-alcoholic steatohepatitis apart from diabetic dyslipidemia. Zydus acquires six brands from MSD
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated December 28, 2016 titled "Zydus acquires six brands from MSD". Clarification
Cadila Healthcare Ltd has informed BSE that :"With reference to a news appearing in the media this morning, we wish to state as under:We wish to clarify that this matter very specifically relates to an Untitled Letter issued by the USFDA to Zydus Discovery DMCC (a 100% subsidiary of Cadila Healthcare Ltd.) and not a Warning Letter. The letter is related to a product promotion of a drug which is not marketed in USA and currently marketed... Zydus Announces Settlement of a DELZICOL (mesalamine) Patent Litigation
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated December 03, 2016 titled "Zydus Announces Settlement of a DELZICOL (mesalamine) Patent Litigation".